Brief: Mira Pharmaceuticals Announces New Study Results For SKNY-1 - SEC Filing
30/06/2025 12:38
June 30 (Reuters) - Mira Pharmaceuticals Inc MIRA.O: MIRA PHARMACEUTICALS INC - ANNOUNCES NEW STUDY RESULTS FOR SKNY-1 - SEC FILING MIRA PHARMACEUTICALS INC - IN ANIMAL MODEL OF OBESITY & CRAVING USING SKNY-1 REDUCED BODY WEIGHT BY APPROXIMATELY 30% AFTER JUST SIX DAYS MIRA PHARMACEUTICALS INC - TREATED ANIMALS WEIGH 10% LESS THAN HEALTHY CONTROLS - SEC FILING MIRA PHARMACEUTICALS: IN UNTREATED OBESE ANIMALS, FAT BUILDUP IN THE LIVER WAS ABOUT 50% HIGHER THAN NORMAL Source text: [ID:n0001641172-25-017046] Further company coverage: MIRA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mira Pharmaceuticals
See all newsBrief: Mira Pharmaceuticals - Alan Weichselbaum To Step Down As CFO Effective June 6, 2026 - SEC Filing
Brief: MIRA Pharmaceuticals Secures Worldwide Exclusive Rights To MIRA-55 And SKNY-1 - SEC Filing
Brief: Mira Pharmaceuticals Enters Into Amendment No 1 To Exclusive License Agreement With Miralogx
Brief: Mira Pharmaceuticals Inc - Completes Phase 1 Dosing Of Ketamir-2 - SEC Filing
Brief: Mira Pharmaceuticals Inc - Initiates Phase 1 Study Of Ketamir-2 - SEC Filing